Petrakis Ioannis, Drosataki Eleni, Lygerou Dimitra, Antonakis Andreas, Kydonaki Konstantina, Mitrakos Marinos, Pleros Christos, Sfakiotaki Maria, Xekouki Paraskevi, Stylianou Kostas
Department of Nephrology, University of Crete, Voutes, 70500 Heraklion, Crete, Greece.
Department of Endocrinology, University of Crete, Voutes, 70500 Heraklion, Crete, Greece.
J Clin Med. 2025 Aug 2;14(15):5447. doi: 10.3390/jcm14155447.
Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant disorder caused by mutations in the MEN1 gene. Although primarily characterized by endocrine tumors, renal manifestations remain underreported. We report a three-generation family carrying a pathogenic mutation (c.1351-3_1359del) with a co-occurring () variant (c.324+13C>G). Genetic testing included MLPA and whole-exome sequencing (WES), with bioinformatics analysis validating variant pathogenicity. All three patients exhibited primary hyperparathyroidism, hypercalcemia, hypercalciuria, early nephrocalcinosis, and renal hypomagnesemia. The CLDN16 variant, previously considered benign, co-segregated with hypomagnesemia and renal involvement, suggesting a potential modifying role. These findings support the need for comprehensive genetic screening in MEN1 patients with atypical renal presentations. Concomitant genetic variations can alter the principal phenotype.
1型多发性内分泌腺瘤病(MEN1)是一种由MEN1基因突变引起的罕见常染色体显性疾病。虽然主要特征为内分泌肿瘤,但肾脏表现的报道仍然较少。我们报告了一个携带致病突变(c.1351-3_1359del)并伴有一个()变异(c.324+13C>G)的三代家族。基因检测包括多重连接探针扩增(MLPA)和全外显子组测序(WES),生物信息学分析验证了变异的致病性。所有三名患者均表现为原发性甲状旁腺功能亢进、高钙血症、高钙尿症、早期肾钙质沉着症和肾脏低镁血症。先前认为良性的CLDN16变异与低镁血症和肾脏受累共分离,提示其可能具有修饰作用。这些发现支持对具有非典型肾脏表现的MEN1患者进行全面基因筛查的必要性。伴随的基因变异可改变主要表型。